Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Roivant Sciences Ltd.
Roivant Sciences Ltd. ROIV | 0.00 |
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:
ROIV) with a Buy and raises the price target from $42 to $46.
